Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 03:40 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Boehringer partners with Simcere to develop a bispecific antibody that simultaneously inhibits two drivers of inflammatory bowel disease.